The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oral etoposide monotherapy for Chinese patients with metastatic breast cancer: Efficacy and tolerance regardless of heavy prior therapy.
P. Yuan
No relevant relationships to disclose
B. Xu
No relevant relationships to disclose
F. Ma
No relevant relationships to disclose
J. Wang
No relevant relationships to disclose
Y. Fan
No relevant relationships to disclose